Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2554 - FICHE-YOUNG: FIrst-line treatment CHoicE in hormone receptor positive (HR+)/ HER2- negative metastatic breast cancer patients (MBC) ≤45 years old. A large observational multicenter cohort survival analysis.

Date

11 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Breast Cancer

Presenters

BARBARA PISTILLI

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

B. PISTILLI1, A. Lardy-Cleaud2, E. JACQUET3, S. Delaloge1, P. Cottu4, M. Debled5, L. Vanlemmens6, M. Leheurteur7, F. Divanon8, A. Gonçalves9, C. Laurent10, B. Coudert11, E. Chamorey12, L. Campion13, M. Mouret-Reynier14, M. Breton15, T. Petit16, G. Simon17, C. Cailliot18, T. Bachelot3

Author affiliations

  • 1 Breast Cancer, GUSTAVE ROUSSY, 94800 - Villejuif/FR
  • 2 Biostatistics, Centre Leon Bérard, 69008 - Lyon/FR
  • 3 Medical Oncology, Centre Leon Berard, 69008 - Lyon/FR
  • 4 Oncology, Institut Curie, 75248 cedex5 - Paris/FR
  • 5 Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 6 Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 7 Oncology, Centre Henri Becquerel, 76038 - Rouen/FR
  • 8 Pharmacie, CRLCC FRANCOIS BACLESSE, 14076 - CAEN/FR
  • 9 Oncology, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 10 Oncology, INSTIUT DE CANCEROLOGIE DE LORRAINE, NANCY/FR
  • 11 Oncology, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 12 Pharmacy, Centre Antoine Lacassagne, 06189 - Nice/FR
  • 13 Biostatistics, Centre Rene Gauducheau, 44800 - Nantes/FR
  • 14 Medical Oncology, Centre Jean Perrin, Clermont-Ferrand/FR
  • 15 Oncology, CENTRE EUGENE-MARQUIS, RENNES/FR
  • 16 Oncology, Centre Paul Strauss Centre de Lutte contre le Cancer, 67065 - Strasbourg/FR
  • 17 R&d, Unicancer R&D, 75013 - Paris/FR
  • 18 R&d, Unicancer R&D, PARIS/FR
More

Resources

Abstract 2554

Background

Metastatic breast cancer (MBC) in young patients (pts) is traditionally considered at poor prognosis. Although current guidelines recommend endocrine therapy (ET) as first line treatment (1st trt) for HR+ HER2- MBC, younger age can lead to more extensive use of first line chemotherapy (CT). In the present analysis, we aimed to assess overall survival (OS) of younger MBC pts compared to older ones, and to explore 1st trt choices in a large real-life multicenter cohort.

Methods

The Epidemiological Strategy and Medical Economics (ESME) Research program aims to collect high-quality real-world data in oncology from 18 French Comprehensive Cancer Centers. Pts who started treatment for a newly diagnosed MBC between Jan 2008 and Dec 2014 were selected in the MBC ESME database. The primary end point of the FICHE-Young study was to compare adjusted OS in pts diagnosed with endocrine-sensitive HR+ HER2- MBC and aged ≤45 vs > 45 at diagnosis. We also evaluated 1st trt choices in both categories and its correlation with OS. Analyses will be adjusted on a propensity score, in order to control selection biases associated with non-randomization.

Results

6265 pts out of 16703 in ESME had HR+/HER2- MBC. Characteristics and 1st trt choices are listed in the Table. Median OS was 62.3 months (mos) (95% CI 56.5-69) in pts ≤45 and 52.8 mos in those >45 (95% CI 50.7-55), p45 yrs oldN8515414Median age40.0 [23;44]63 [45;95]Visceral metastases56.3%51.6%De novo MBC41%42.4%Median time to onset of MBC3.28 yrs [0.50;19.53]9.18 yrs [0.50;43.02]1st trt: ET alone19.4%47.4%Chemo +/- maintenance ET80.6%52.6%

Conclusions

With the limitations of a nonrandomized study population, in this real-world setting, younger HR+MBC pts did not show a poorer prognosis compared to older patients. Many young pts received CT as first line treatment, with no demonstrated benefit over ET alone.

Clinical trial identification

NOT APPLICABLE

Legal entity responsible for the study

UNICANCER

Funding

UNICANCER

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.